ELIQUIS(R) (apixaban) Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement

R), a new oral direct Factor Xa inhibitor being developed by the alliance of Bristol-Myers Squibb Company and Pfizer Inc. "Major orthopedic surgery, such as total knee replacement or total hip replacement, puts patients at a very high risk of developing...